Loading...
Printed on 7/20/2026
For informational purposes only. This is not medical advice.
CHADS2 is a historical atrial fibrillation stroke risk model that assigns points for congestive heart failure, hypertension, age >=75, diabetes, and prior stroke/TIA (2 points). It remains useful for educational context and quick baseline risk framing, although modern practice commonly uses CHA2DS2-VASc for finer stratification.
Formula: CHADS2 = CHF (1) + HTN (1) + Age >=75 (1) + Diabetes (1) + Prior Stroke/TIA (2).
Save your results with a free account
Keep a history of calculations, favorite tools, and access your dashboard anytime.
Assign points for each present risk factor: Congestive Heart Failure or LVEF <40% (1 point), Hypertension — diagnosed or on treatment (1 point), Age ≥75 years (1 point), Diabetes mellitus (1 point), prior Stroke or TIA (2 points). The maximum total score is 6 points. All variables are obtained from the clinical history without requiring laboratory results.
Sum all applicable points: CHADS2 0 = 1.9% annual stroke risk; CHADS2 1 = 2.8%; CHADS2 2 = 4.0%; CHADS2 3 = 5.9%; CHADS2 4 = 8.5%; CHADS2 5 = 12.5%; CHADS2 6 = 18.2%. Prior stroke or TIA is the highest weighted item (2 points), reflecting the particularly high recurrent stroke risk in patients with prior cerebrovascular events.
NOTE: CHA2DS2-VASc is now universally preferred over CHADS2 for anticoagulation decisions per ACC/AHA 2019 and ESC 2020 AF guidelines. Use CHA2DS2-VASc for clinical management. CHADS2 is most useful for educational reference, reviewing historical clinical trial data, or resource-limited settings. Anticoagulation is recommended for CHA2DS2-VASc ≥2 in men and ≥3 in women (NOAC preferred over warfarin).
Cardiologists, electrophysiologists, general physicians
CHADS2 was the standard AF stroke risk tool from 2001-2010 before CHA2DS2-VASc was validated. Understanding CHADS2 is essential for interpreting older clinical trial data, historical cohort studies, and pre-2010 treatment guidelines that reference CHADS2 for anticoagulation decisions.
Medical students, resident physicians, educators
CHADS2 is commonly taught as the foundational AF stroke risk score because its five straightforward risk factors illustrate the core concept of AF stroke risk stratification. It demonstrates the rationale for anticoagulation in AF and provides a clinical framework that students can build upon when learning CHA2DS2-VASc.
Clinicians transitioning to CHA2DS2-VASc, clinical pharmacists
Calculating both CHADS2 and CHA2DS2-VASc for the same patient illustrates how CHA2DS2-VASc identifies additional intermediate-risk patients (age 65-74, vascular disease, female sex) who benefit from anticoagulation but would have been missed by CHADS2 alone. This comparison demonstrates the clinical advantage of the newer score.
All clinicians, patient educators
The five CHADS2 factors — CHF, hypertension, age, diabetes, stroke history — are the core modifiable and non-modifiable AF stroke risk factors. Discussing these with patients in the context of CHADS2 (or CHA2DS2-VASc) helps patients understand why anticoagulation is recommended and motivates risk factor control.
Clinicians in resource-limited settings
In clinical settings where detailed vascular history (coronary disease, PAD, aortic plaque) required for CHA2DS2-VASc may be difficult to ascertain, CHADS2 provides a practical 5-factor approximation. However, CHA2DS2-VASc should be used whenever possible.
Both ACC/AHA 2019 AF Guidelines (January et al., JACC 2019) and ESC 2020 AF Guidelines (Hindricks et al., Eur Heart J 2021) replaced CHADS2 with CHA2DS2-VASc as the recommended stroke risk stratification tool. Use CHA2DS2-VASc for all clinical anticoagulation decisions. CHADS2 is now primarily used for historical reference and education.
CHADS2 scores 0-1 include a heterogeneous group ranging from truly low-risk to intermediate-risk patients. CHA2DS2-VASc better identifies intermediate-risk patients by adding age 65-74 (1 pt), vascular disease (1 pt), and female sex (1 pt). These additions capture patients who CHADS2 misses but who have meaningful stroke risk. CHA2DS2-VASc score 0 in males is the only truly low-risk category not requiring anticoagulation.
A CHADS2 score of 0 does not mean the patient is truly low risk. A patient aged 65-74 with vascular disease and female sex would score CHADS2 = 0 but CHA2DS2-VASc = 3 — indicating meaningful stroke risk that warrants anticoagulation. Always use CHA2DS2-VASc to identify truly low-risk patients (score 0 in males, 1 in females = anticoagulation not recommended).
Prior stroke or TIA is the most powerful single predictor of recurrent stroke in AF, reflecting both the established cardioembolic mechanism and the vulnerable cerebrovascular state. It contributes 2 points to CHADS2 and 2 points to CHA2DS2-VASc. Patients with prior stroke/TIA have approximately 10-12% annual recurrent stroke risk without anticoagulation — anticoagulation is strongly indicated regardless of other factors.
Apixaban, rivaroxaban, dabigatran, and edoxaban are preferred over warfarin for non-valvular AF anticoagulation per ACC/AHA and ESC guidelines. NOACs have equivalent or superior efficacy, lower intracranial hemorrhage risk, and simpler management (no INR monitoring). Warfarin remains preferred for AF with mitral stenosis or mechanical heart valves, where NOACs are not approved.
Atrial flutter has the same thromboembolic risk as AF and requires the same anticoagulation approach guided by CHADS2 or CHA2DS2-VASc score. Many patients with flutter also have AF, and flutter itself promotes atrial structural remodeling. Do not withhold anticoagulation from AFL patients with high stroke risk scores on the basis that the rhythm is 'not AF.'
Patients who undergo cardioversion or catheter ablation and maintain sinus rhythm still require continued anticoagulation if their CHA2DS2-VASc score warrants it. Even successfully rhythm-controlled patients may have brief asymptomatic AF recurrences detected by implantable monitors. Long-term anticoagulation should be based on CHA2DS2-VASc score, not presumed freedom from AF.
HAS-BLED score assesses bleeding risk in AF anticoagulation: H (hypertension), A (abnormal renal/liver function), S (stroke history), B (bleeding history or predisposition), L (labile INR), E (elderly, age >65), D (drugs/alcohol). HAS-BLED ≥3 indicates high bleeding risk — address modifiable bleeding risk factors (blood pressure control, NSAIDs discontinuation) rather than withholding anticoagulation, which remains net beneficial in most high-CHA2DS2-VASc patients.
CHADS2 and CHA2DS2-VASc were developed and validated for non-valvular AF. Patients with AF and rheumatic mitral stenosis or mechanical heart valves require anticoagulation (warfarin, not NOACs) regardless of CHADS2/CHA2DS2-VASc score — the indication is absolute. NOACs are specifically not approved for AF with moderate-severe mitral stenosis or mechanical valves.
Higher CHADS2 scores reflect increasing annual thromboembolic stroke risk in non-valvular atrial fibrillation.
Use this score for quick educational AF stroke risk framing or when reviewing historical literature that reports CHADS2 cohorts.
CHADS2 is less granular than CHA2DS2-VASc and may under-classify risk in some patients. It should not replace full modern risk-benefit assessment.
Disclaimer: This tool is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about your health.
April 21, 2026 · trust-baseline
Clinical trust metadata enabled for this tool page with structured review/version fields.
Calculate the CHA₂DS₂-VASc score to estimate stroke risk in patients with atrial fibrillation and guide anticoagulation therapy decisions.
OpenCardiologyCalculate the HAS-BLED score to assess bleeding risk in patients on anticoagulation therapy. Balance stroke prevention against bleeding risk.
OpenCardiologyCalculate the TIMI risk score for NSTEMI and unstable angina to predict 14-day adverse cardiac events.
OpenCardiologyCalculate 10-year ASCVD risk using current 2026 ACC/AHA Pooled Cohort Equations. Statin thresholds: <5% low, 5–7.5% borderline, ≥7.5% intermediate, ≥20% high.
Open